FDA Approves Gene Therapy for Kids 2+ With Sickle Cell

Children as young as 2 can now access a breakthrough gene therapy that could eliminate the need for lifelong blood transfusions.

The FDA just expanded approval of Casgevy, a one-time CRISPR treatment that edits a patient's own cells to fight sickle cell disease.